Choosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care

Similar documents
Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the

Psychotropic Medication. Including Role of Gradual Dose Reductions

2. Did the member receive this medication during a recent hospitalization? Y N

2. Did the patient receive this medication during a recent hospitalization? Y N

Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia

Aggression (Severe) in Children under Age 6

Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology

New Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services

PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE

Managing Behavioural Problems in Patients with Learning Disabilities

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD

Medication Audit Checklist- Antipsychotics - Atypical

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services

White Paper: The Treatment of Schizophrenia and Bipolar Disorder

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

EARLY ONSET SCHIZOPHRENIA

Psychosis and Agitation in Dementia

Pharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Table of Contents. 1.0 Policy Statement...1

BlueCare Tennessee Practice Guidance For the Treatment of Schizophrenia Kelly Askins, MD and Deborah Gatlin, MD 3/9/2015 Reviewed: February, 2017

Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?

Training Presentation

Mood Disorders for Care Coordinators

NCI Data Brief. ISSUE 6 December 2012

CASE 5 - Toy & Klamen CASE FILES: Psychiatry

File NDA SE5 046/047, NDA SE5 036/037, NDA SE5 020/021

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

Antipsychotic Prior Authorization Request

FAMILY FUNCTIONAL THERAPY (FFT)

Psychotropic Medication

POLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 2012 PSYCHOPHARMACOLOGY SERIES. Guna Kanniah Waikato Hospital

INTERQUAL BEHAVIORAL HEALTH CRITERIA GERIATRIC PSYCHIATRY REVIEW PROCESS

PRESCRIBING GUIDELINES

Psychotropics and Foster Care: Challenge or Opportunity?

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Disclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013

The Maudsley Prescribing Guidelines in

Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID

Prescribing for people with a personality disorder. POMH-UK QIP 12b

Pharmacotherapy of psychosis and schizophrenia in youth

2. You must remain available until at least 5:00PM each day unless approved by the Attending and Resident.

Behavioural Symptoms of Dementia

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline

Understanding Bipolar Disorder

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

CLINICAL EFFECTIVENESS

4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue

Pediatric Primary Care Mental Health Specialist Certification Exam. Detailed Content Outline

Talking to Patients and Their Families

UNDERSTANDING BIPOLAR DISORDER Caregiver: Get the Facts

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Class Update: Oral Antipsychotics

INFORMED CONSENT FOR PSYCHOTROPIC MEDICATION

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

Drugs, Society and Behavior

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder

Multiple choice questions: ANSWERS

9/11/2012. Clare I. Hays, MD, CMD

Clinical Guideline for the Management of Bipolar Disorder in Adults

PORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016

Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics

Is Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?

Aggression (Severe) in Children under Age 6

Scholarly Activity Portfolio Page. Subspecialty national or international Local

Dr Keith Ganasen Department of Psychiatry UCT

Pediatric Psychopharmacology

New Guidelines for Opioid Prescribing

Drugs used to relieve behavioural and psychological symptoms in dementia

Choosing and delivering ering interventions entions for

CLINICAL EFFECTIVENESS

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

Mental Health Current Articles Bulletin - April 2017

Adult Mental Health Services applicable to Members in the State of Connecticut subject to state law SB1160

Application of Psychotropic Drugs in Primary Care

Practical Considerations Related to Pharmacology and Developmental Disabilities

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care

First Steps: Considering Clozapine for your Patients

PDF of Trial CTRI Website URL -

Rational Medication Use in Dementia

Antipsychotic Medications Age and Step Therapy

Bipolar Disorder in Youth

Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations

Pediatric Imaging Spine MRI and Spine CT Test Request Tip Sheet

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

RMP version 3.0 Aripiprazole

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Antidepressants for treatment of depression.

Minimising the Impact of Medication on Physical Health in Schizophrenia

Management of Behavioral Problems in Dementia

5 COMMON QUESTIONS WHEN TREATING DEPRESSION

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Mental Health Disorders Civil Commitment UNC School of Government

Transcription:

Choosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care JASON BEAMAN D.O., M.S., FAPA ASSISTANT CLINICAL PROFESSOR CHAIR, DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES OKLAHOMA STATE UNIVERSITY Board Certified: Forensic Psychiatry Psychiatry Family Medicine

Objectives Understand the history and background of Choosing Wisely Understand the 5 APA Choosing Wisely Points Understand the basis of the 5 APA Choosing Wisely Points

About the Campaign An initiative of the American Board of Internal Medicine Foundation Started in 2012 Intended to provide the foundation of a conversation between physician and patient

About the Campaign Intent is to prevent the overuse of tests and procedures Engages the patient to make smart and effective care choices Involves leading healthcare organizations and Consumer Reports

About the Campaign Choosing Wisely is part of a multi-year effort of the ABIM Foundation to help physicians and other health care providers be better stewards of finite health care resources.

About the Campaign Each organization provides a brief list of Things to Question This list addresses common misconceptions and poor practice habits related to that organization Each item is a specific evidence based recommendation

Analyzing Things to Question Start with the Organization Each physician should be aware of their own organizations recommendations Each physician should be aware of the organizations that may be applicable

Organizations

Analyzing Things to Question Look at the Recommendation Short one sentence Very specific

Analyzing Things to Question Read the explanation Look at the sources

Example-Recommendation Don t prescribe antibiotics for otitis media in children aged 2-12 years with non-severe symptoms where the observation option is reasonable.

Example-Reasoning The observation option refers to deferring antibacterial treatment of selected children for 48 to 72 hours and limiting management to symptomatic relief. The decision to observe or treat is based on the child s age, diagnostic certainty and illness severity. To observe a child without initial antibacterial therapy, it is important that the parent or caregiver has a ready means of communicating with the clinician. There also must be a system in place that permits reevaluation of the child.

Sources Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, Joffe MD, Miller DT, Rosenfeld RM, Sevilla XD, Schwartz RH, Thomas PA, Tunkel DE, American Academy of Pediatrics, American Academy of Family Physicians. The diagnosis and management of acute otitis media. Pediatrics. 2013 Mar;131(3):e964 99. Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM. Antibiotics for acute otitis media in children. Cochrane Database Syst Rev. 2013 Jan 31;1:CD000219.

Exclusion These items are provided solely for informational purposes and are not intended as a substitute for consultation with a medical professional. Patients with any specific questions about the items on this list or their individual situation should consult their physician.

American Psychiatric Association Founded in 1844 36,500 members More than 100 countries

American Psychiatric Association

#1 Don t prescribe antipsychotic medications to patients for any indication without appropriate initial evaluation and appropriate ongoing monitoring.

#1 Metabolic, neuromuscular and cardiovascular side effects are common in patients receiving antipsychotic medications for any indication, so thorough initial evaluation to ensure that their use is clinically warranted, and ongoing monitoring to ensure that side effects are identified, are essential.

#1 Appropriate initial evaluation includes the following: a) Thorough assessment of possible underlying causes of target symptoms including general medical, psychiatric, environmental or psychosocial problems b) Consideration of general medical conditions c) Assessment of family history of general medical conditions, especially of metabolic and cardiovascular disorders

#1 Appropriate ongoing monitoring includes: a) Re-evaluation and documentation of dose, efficacy and adverse effects b) Assessment of movement disorder or neurological symptoms c) Assessment of metabolic measurements: a) weight, waist circumference and/or BMI b) blood pressure c) heart rate d) blood glucose level e) lipid profile at periodic intervals

#1 Re-evaluation and documentation of dose, efficacy and adverse effects: Need to check status of the condition Constantly need to ensure that benefits outweigh the risk *To prescribe antipsychotics without follow-up and re-evaluation is irresponsible and below the standard of care

#1 Assessment of movement disorder or neurological symptoms All antipsychotics carry a risk of neurological conditions: Tardive Dyskinesia Dystonia Akesthesia Monitor Tardive Dyskinesia with AIMS

AIMS

AIMS

#1 Assessment of metabolic measurements Patients with schizophrenia are at increased risk of Metabolic Syndrome, CAD and Diabetes Antipsychotics increases this risk From 1996-2001, 3.1-10% of all Diabetes was attributed to the use of atypical antipsychotics

#2 Don t routinely prescribe two or more antipsychotic medications concurrently.

#2 Research shows that use of two or more antipsychotic medications occurs in 4 to 35% of outpatients and 30 to 50% of inpatients. However, evidence for the efficacy and safety of using multiple antipsychotic medications is limited, and risk for drug interactions, noncompliance and medication errors is increased.

#2 Generally, the use of two or more antipsychotic medications concurrently should be avoided except in cases of three failed trials of monotherapy, which included one failed trial of Clozapine where possible, or where a second antipsychotic medication is added with a plan to cross-taper to monotherapy.

#2 Essentially you get all the risks with no benefits Be vigilant at times when there are multiple physicians Be vigilant at times of transition of care Stresses the importance of medication reconciliation

#3 Don t routinely use antipsychotics as first choice to treat behavioral and psychological symptoms of dementia

#3 Behavioral and psychological symptoms of dementia are defined as the non-cognitive symptoms and behaviors, including agitation or aggression, anxiety, irritability, depression, apathy and psychosis. Evidence shows that risks (e.g., cerebrovascular effects, mortality, parkinsonism or extrapyramidal signs, sedation, confusion and other cognitive disturbances, and increased body weight) tend to outweigh the potential benefits of antipsychotic medications in this population.

#3 Clinicians should generally limit the use of antipsychotic medications to cases where non-pharmacologic measures have failed and the patients symptoms may create a threat to themselves or others. This item is also included in the American Geriatric Society s list of recommendations for Choosing Wisely.

APA Things To Question #3

#3 Not a clear pharmacologic mechanism for action for antipsychotics in dementia Demonstrated harm Can have some beneficial properties Very important to discuss risk/benefits with decision maker and document such

#4 Don t routinely prescribe antipsychotic medications as a first-line intervention for insomnia in adults.

#4 There is inadequate evidence for the efficacy of antipsychotic medications to treat insomnia (primary or due to another psychiatric or medical condition), with the few studies that do exist showing mixed results

#4 But I ve tried everything else But it works for me Its ok because it s a low dose

Medications used to treat sleep

#4 There are A LOT of options that are much more effective and have much less side effects than antipsychotics when used for sleep The default of the body and mind is to sleep If not occurring, then regular medicine needs to happen diagnosis Should not routinely use sleep meds long term without workup and evaluation

#5 Don t routinely prescribe an antipsychotic medication to treat behavioral and emotional symptoms of childhood mental disorders in the absence of approved or evidence supported indications.

#5 There are both on and off label clinical indications for antipsychotic use in children and adolescents. FDA approved and/or evidence supported indications for antipsychotic medications in children and adolescents include psychotic disorders, bipolar disorder, tic disorders, and severe irritability in children with autism spectrum disorders; there is increasing evidence that antipsychotic medication may be useful for some disruptive behavior disorders.

#5 Children and adolescents should be prescribed antipsychotic medications only after having had a careful diagnostic assessment with attention to comorbid medical conditions and a review of the patient s prior treatments. Efforts should be made to combine both evidence-based pharmacological and psychosocial interventions and support. Limited availability of evidence based psychosocial interventions may make it difficult for every child to receive this ideal combination.

#5 Discussion of potential risks and benefits of medication treatment with the child and their guardian is critical. A short and long term treatment and monitoring plan to assess outcome, side effects, metabolic status and discontinuation, if appropriate, is also critical. The evidence base for use of atypical antipsychotics in preschool and younger children is limited and therefore further caution is warranted in prescribing in this population.

#5 The physician prescribing this serious medication to children needs to be on solid ground: Must have accurate diagnosis Must monitor at adult recommendations Must document informed consent with parents

#5 A child suspected of having a psychotic or bipolar disorder should be evaluated by a Child and Adolescent Psychiatrist A child with behavior problems needs a serious discussion about behavior modification

Summary 1. Don t prescribe antipsychotic medications to patients for any indication without appropriate initial evaluation and appropriate ongoing monitoring. 2. Don t routinely prescribe two or more antipsychotic medications concurrently. 3. Don t routinely use antipsychotics as first choice to treat behavioral and psychological symptoms of dementia 4. Don t routinely prescribe antipsychotic medications as a first-line intervention for insomnia in adults. 5. Don t routinely prescribe an antipsychotic medication to treat behavioral and emotional symptoms of childhood mental disorders in the absence of approved or evidence supported indications.

Questions?